NCT02228980View on ClinicalTrials.gov

Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

PHASE4CompletedINTERVENTIONAL
Enrollment

602

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

October 31, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation

0.25 mL Intramuscular (2 doses given 28 days apart)

BIOLOGICAL

Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation

0.5 mL Intramuscular

BIOLOGICAL

Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation

0.5 mL Intramuscular

BIOLOGICAL

Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation

0.5 mL Intramuscular

Trial Locations (1)

Unknown

Nanning

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02228980 - Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China | Biotech Hunter | Biotech Hunter